Integrative analysis of multi-omics data for discovery of ferroptosis-related gene signature predicting immune activity in neuroblastoma.

ferroptosis gene immune neuroblastoma survival

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2023
Historique:
received: 09 02 2023
accepted: 02 06 2023
medline: 31 7 2023
pubmed: 31 7 2023
entrez: 31 7 2023
Statut: epublish

Résumé

Immunotherapy for neuroblastoma remains unsatisfactory due to heterogeneity and weak immunogenicity. Exploring powerful signatures for the evaluation of immunotherapy outcomes remain the primary purpose. We constructed a ferroptosis-related gene (FRG) signature by least absolute shrinkage and selection operator and Cox regression, identified 10 independent prognostic FRGs in a training cohort (GSE62564), and then verified them in an external validation cohort (TCGA). Associated with clinical factors, the signature accurately predicts overall survival of 3, 5, and 10 years. An independent prognostic nomogram, which included FRG risk, age, stage of the International Neuroblastoma Staging System, and an MYCN status, was constructed. The area under the curves showed satisfactory prognostic predicting performance. Through bulk RNA-seq and proteomics data, we revealed the relationship between hub genes and the key onco-promoter MYCN gene and then validated the results in MYCN-amplified and MYCN-non-amplified cell lines with qRT-PCR. The FRG signature significantly divided patients into high- and low-risk groups, and the differentially expressed genes between the two groups were enriched in immune actions, autophagy, and carcinogenesis behaviors. The low-risk group embodied higher positive immune component infiltration and a higher expression of immune checkpoints with a more favorable immune cytolytic activity (CYT). We verified the predictive power of this signature with data from melanoma patients undergoing immunotherapy, and the predictive power was satisfactory. Gene mutations were closely related to the signature and prognosis. AURKA and PRKAA2 were revealed to be nodal hub FRGs in the signature, and both were shown to have significantly different expressions between the INSS stage IV and other stages after immunohistochemical validation. With single-cell RNA-seq analysis, we found that genes related to T cells were enriched in TNFA signaling and interferon-γ hallmark. In conclusion, we constructed a ferroptosis-related gene signature that can predict the outcomes and work in evaluating the effects of immunotherapy.

Identifiants

pubmed: 37521469
doi: 10.3389/fphar.2023.1162563
pii: 1162563
pmc: PMC10373597
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1162563

Informations de copyright

Copyright © 2023 Hu, Song, Kang, Xia, Song, Wang, Li and Zhao.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

PLoS One. 2012;7(10):e46928
pubmed: 23071666
Front Cell Dev Biol. 2022 Jan 06;9:769580
pubmed: 35071226
Cell Death Dis. 2019 Feb 25;10(3):193
pubmed: 30804337
Cancer Cell. 2009 Jan 6;15(1):67-78
pubmed: 19111882
J Cancer. 2020 Feb 10;11(9):2390-2400
pubmed: 32201510
Clin Cancer Res. 2017 Feb 1;23(3):804-813
pubmed: 27756784
Trends Cancer. 2021 Oct;7(10):891-901
pubmed: 34023326
Cold Spring Harb Perspect Med. 2013 Oct 01;3(10):a014415
pubmed: 24086065
Int Immunopharmacol. 2021 May;94:107499
pubmed: 33640859
Methods Mol Biol. 2016;1418:111-41
pubmed: 27008012
Int J Cancer. 2021 Mar 1;148(5):1219-1232
pubmed: 33284994
EMBO J. 2021 Feb 1;40(3):e105784
pubmed: 33411331
CNS Neurosci Ther. 2015 Jul;21(7):549-57
pubmed: 26010513
Eur J Cancer. 2020 Sep;136:52-68
pubmed: 32653773
Pharmacology. 2011;87(3-4):121-9
pubmed: 21304223
Cells. 2019 Sep 08;8(9):
pubmed: 31500396
JAMA Oncol. 2018 Dec 1;4(12):1691-1698
pubmed: 30098163
Front Oncol. 2020 Aug 19;10:1411
pubmed: 32974147
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Front Cell Dev Biol. 2020 Dec 23;8:596679
pubmed: 33425905
Expert Rev Anticancer Ther. 2017 Apr;17(4):369-386
pubmed: 28142287
Int J Mol Sci. 2020 Jul 22;21(15):
pubmed: 32707907
Cancer Lett. 2013 Jan 28;328(2):198-206
pubmed: 23022474
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Cancer Cell Int. 2020 Jan 07;20:9
pubmed: 31920463
Front Oncol. 2021 Jul 30;11:710694
pubmed: 34395285
Cancer Cell. 2019 Feb 11;35(2):238-255.e6
pubmed: 30753825
Klin Padiatr. 2013 Nov;225(6):303-8
pubmed: 24166094
Antioxidants (Basel). 2021 Apr 28;10(5):
pubmed: 33924765
J Mol Diagn. 2020 Jan;22(1):3-20
pubmed: 31605800
Biochem Pharmacol. 2020 Oct;180:114167
pubmed: 32702370
Biomed Res Int. 2018 Feb 25;2018:1812535
pubmed: 29682521
Oncoimmunology. 2021 Jun 30;10(1):1933332
pubmed: 34262797
Clin Transl Oncol. 2015 Jan;17(1):50-6
pubmed: 25015721
Oncoimmunology. 2013 Mar 1;2(3):e23618
pubmed: 23802089
Cancer Res. 2011 Jun 15;71(12):4292-302
pubmed: 21507930
Clin Immunol. 2020 Feb;211:108343
pubmed: 31931123
Immunol Rev. 2017 May;277(1):150-157
pubmed: 28462529
Cell Immunol. 1999 Nov 1;197(2):75-82
pubmed: 10607424
Free Radic Biol Med. 2014 Apr;69:367-76
pubmed: 24512906
Cancer Res. 2018 Dec 1;78(23):6575-6580
pubmed: 30154154
Fetal Pediatr Pathol. 2022 Jun;41(3):355-370
pubmed: 32901528
J Cell Mol Med. 2019 Mar;23(3):1687-1697
pubmed: 30636376
Cancer Res. 2011 Feb 15;71(4):1385-95
pubmed: 21303981
J Cell Biol. 1986 Mar;102(3):688-96
pubmed: 3005335
Cancer Immunol Immunother. 2021 Aug;70(8):2339-2351
pubmed: 33512556
J Clin Oncol. 2005 Sep 20;23(27):6459-65
pubmed: 16116153
BMC Med Genomics. 2020 Nov 10;13(1):171
pubmed: 33172452
Cell Death Differ. 2016 Mar;23(3):369-79
pubmed: 26794443
Annu Rev Med. 2015;66:49-63
pubmed: 25386934
Nat Rev Clin Oncol. 2021 May;18(5):280-296
pubmed: 33514910
Sci Transl Med. 2018 May 16;10(441):
pubmed: 29769286
Redox Biol. 2018 Jul;17:338-347
pubmed: 29793167
J Immunother Cancer. 2018 Dec 27;6(1):157
pubmed: 30587233
Cartilage. 2021 Dec;13(2_suppl):1030S-1040S
pubmed: 34459260
Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3336-41
pubmed: 21289283
Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):3826-3836
pubmed: 29949159
Mol Cancer. 2021 Jan 15;20(1):15
pubmed: 33451333
Carcinogenesis. 2020 May 14;41(3):284-295
pubmed: 31605138
Nat Rev Cancer. 2019 Jul;19(7):405-414
pubmed: 31101865
Surg Oncol. 2007 Nov;16(3):149-56
pubmed: 17976976
Mol Cell. 2016 Nov 3;64(3):493-506
pubmed: 27773673
Dis Markers. 2012;32(5):309-20
pubmed: 22674411
J Clin Invest. 2020 Jul 1;130(7):3848-3864
pubmed: 32315290
Cancer Lett. 2021 Jul 1;509:89-104
pubmed: 33848520
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Eur Spine J. 2020 Sep;29(9):2231-2242
pubmed: 32342280
Cancer Res. 2019 Mar 15;79(6):1151-1164
pubmed: 30541743
Front Cell Dev Biol. 2021 Aug 12;9:709398
pubmed: 34458267
Int J Clin Oncol. 2012 Jun;17(3):196-203
pubmed: 22588779
Neurochem Int. 2015 Nov;90:152-65
pubmed: 26265052
Histopathology. 1982 Jan;6(1):81-92
pubmed: 6120137
Cell Death Differ. 2021 Oct;28(10):2843-2856
pubmed: 34465893
Cancer Immunol Immunother. 2011 Oct;60(10):1485-95
pubmed: 21660451
Autophagy. 2020 Nov;16(11):2069-2083
pubmed: 31920150
Cancer Med. 2015 Apr;4(4):540-50
pubmed: 25653133
Cancer Gene Ther. 2020 Apr;27(3-4):147-167
pubmed: 31164716
J Proteome Res. 2019 Nov 1;18(11):3850-3866
pubmed: 31560547
Front Cell Dev Biol. 2021 Jul 07;9:684259
pubmed: 34307361
Int J Oral Maxillofac Implants. 2021 Sep-Oct;36(5):1016-1023
pubmed: 34698729
Nat Commun. 2013;4:2612
pubmed: 24113773
Free Radic Biol Med. 2021 Jun;169:271-282
pubmed: 33895289
Cell Death Dis. 2021 May 19;12(6):511
pubmed: 34011924
J Public Health Res. 2017 Dec 13;6(3):1001
pubmed: 29291192
Cancers (Basel). 2020 May 13;12(5):
pubmed: 32414098
J Immunol Res. 2018 Oct 30;2018:8097398
pubmed: 30510968
Acta Biochim Biophys Sin (Shanghai). 2019 Nov 18;51(11):1134-1141
pubmed: 31650158
Cell Rep Med. 2022 Jun 21;3(6):100657
pubmed: 35688160
Cancer Res. 2019 Apr 1;79(7):1293-1294
pubmed: 30936073
Genome Biol. 2014 Dec 03;15(12):523
pubmed: 25633159
J Alzheimers Dis. 2016 Sep 6;54(2):535-47
pubmed: 27472877
Eur J Cancer. 2021 Feb;144:123-150
pubmed: 33341446
Genes (Basel). 2017 Mar 30;8(4):
pubmed: 28358317
Biochem Pharmacol. 2021 Nov;193:114747
pubmed: 34454931
Mol Cell. 2005 Apr 29;18(3):283-93
pubmed: 15866171
J Immunol. 2017 Feb 15;198(4):1575-1584
pubmed: 28062694
Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20760-20769
pubmed: 31548371
Nat Med. 2018 Oct;24(10):1545-1549
pubmed: 30127394

Auteurs

Jiajian Hu (J)

Tianjin Key Laboratory of Cancer Prevention and Therapy, Department of Pediatric Oncology, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Fengju Song (F)

Key Laboratory of Molecular Cancer Epidemiology, Department of Epidemiology and Biostatistics, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Wenjuan Kang (W)

Key Laboratory of Molecular Cancer Epidemiology, Department of Epidemiology and Biostatistics, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Fantong Xia (F)

Tianjin Key Laboratory of Cancer Prevention and Therapy, Department of Pediatric Oncology, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Zi'an Song (Z)

Tianjin Key Laboratory of Cancer Prevention and Therapy, Department of Pediatric Oncology, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Yangyang Wang (Y)

Tianjin Key Laboratory of Cancer Prevention and Therapy, Department of Pediatric Oncology, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Jie Li (J)

Tianjin Key Laboratory of Cancer Prevention and Therapy, Department of Pediatric Oncology, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Qiang Zhao (Q)

Tianjin Key Laboratory of Cancer Prevention and Therapy, Department of Pediatric Oncology, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Classifications MeSH